Results 506 cases were discussed via email (n=257) or via phone calls (n=249), and this only included logged phone calls (mean 1.9 referrals per working day). This is an underestimation of the number of calls received because phone calls documented on the electronic patient record were not accessible and therefore not included. The number of cases discussed via email is not a reflection of the number of emails, as each case may have involved several emails. Table 1 shows the reasons for referral. The outcome of the referrals included advice (33.6%,n=170), advice and pleural clinic follow up (23.7%, n=120), advice and scheduling for a pleural procedure (42.7%,n=216) . Of the 216 scheduled for procedures, 49.1% (n=106) were scheduled for a procedure by the pleural team (n=29 pleural one-stop-shop appointments for procedure and review), 49.1% (n=106) were scheduled for a procedure by the radiology team, 1.4% (n=3) were scheduled for an initial procedure by the radiology team (pleural fluid aspiration) then a further procedure by the pleural team (indwelling pleural catheter insertion(n=2), medical thoracoscopy(n=1)), 0.5% (n=1) were scheduled for bronchoscopy. An analysis of the referrals revealed that 22 unnecessary procedures and clinic appointments were avoided after discussion with the pleural team including new pleural outpatient referrals (n=4), follow up pleural outpatient appointment(n=10), pleural procedure appointment (n=5), referral to another clinic(n=2), CT scan (n=1). Advice given on the most appropriate investigation, such as advising large volume aspiration rather than chest drain insertion and hospital admission for a new undiagnosed pleural effusion, was not quantifiable in this retrospective study. Discussion Pleural on-call service is beneficial and can help avoid unnecessary clinic and procedure list appointments. Background Adenocarcinoma is the commonest type of lung cancer and may present with metastatic malignant pleural effusion (MPE) 1 We observed that some patients with pulmonary adenocarcinoma diagnosed at LAT did not have radiological evidence of primary lung parenchymal lesion. We hypothesised that these patients may have a better prognosis than those with lung nodules or masses due to reduced tumour burden. Methods We retrospectively reviewed all patients who underwent LAT from 2006-2016 and screened those diagnosed with pulmonary adenocarcinoma. We reviewed these patients' radiology, age, gender, TNM staging and prognosis. Results 491 patients underwent LAT from 2006-2016. 69/491 (14.05%) were diagnosed with pulmonary adenocarcinoma on histology of parietal pleura. 8 patients out of 69 (3 females, 5 males; mean age 68.25 years) did not have any radiologically detectable lung parenchymal lesion. The TNM staging (7th edition) of these eight patients without lung parenchymal lesion was T0N0M1a, T0N2M1a, T0N2M1a, T0N3M1a, T0N3M1a, T0N0M1b, T0N1M1b, T0N2M1b. Overall prognosis of MPE with lung parenchymal lesion was 331.7+/-63.14 days and without lung parenchymal lesion was 143.5 +/-32.8 days, p=0.31 (figure 1) Conclusion We have demonstrated no significant difference in the prognosis of patients with MPE secondary to pulmonary adenocarcinoma in the absence or presence of a radiologically determined primary lung parenchymal lesion. Although not statistically different (p=0.31) those patients without a primary lung parenchymal lesion may have a worse prognosis and this requires further investigation in larger cohorts as this may prove to be an important prognostic factor for MPE. Introduction Accurate prognostication is difficult in Malignant Pleural Mesothelioma (MPM). Published prognostic models antedate optimal staging, a range of emerging predictors and use methods that cannot be up-scaled to incorporate these. Most existing models allocate patients to risk groups rather than precisely predicting survival. We developed robust computational models that can be up-scaled and provide quantitative statistics regarding the predictions offered. Here we report their performance using routinely available clinical data, on which previous models are based. Materials and Methods Baseline information regarding 20 candidate predictors was collected for 269 MPM patients diagnosed in the West of Scotland (January 2008 -April 2014). Patients were allocated to balanced training (n=169) and validation sets (n=100). Prognostic signatures (minimal length best-performing multivariate trained models) were generated by Least Absolute Shrinkage and Selection Operator (Lasso) regression for Overall Survival (OS), OS<6 months and OS<12 months. OS prediction was quantified using Somers D XY statistic, which varies from 0 to 1, with increasing concordance between observed and predicted outcomes. 6-and 12 month survival were described by area under the curve (AUC) scores. Results Median OS was 270 (IQR 140-450) days. The primary OS model assigned high weights to 4 predictors: age, performance status, white cell count and serum albumin, and after cross-validation performed significantly better than would be expected by chance (mean D XY 0.332 (+/-0.019) figure 1) . However, validation set D XY was only 0.221 (0.0935-0.346), equating to a 22% improvement in survival prediction than would be expected by chance. 6-and 12 month OS signatures included the same 4 predictors, in addition to epithelioid histology plus platelets and epithelioid histology plus C-reactive protein (mean AUC 0.758 (+/-0.022) and 0.737 (+/-0.012), respectively). The <6 month OS model demonstrated 74% sensitivity and 68% specificity. The <12 month OS model demonstrated 63% sensitivity and 79% specificity. Model content and performance were generally comparable with previous studies. Discussion The prognostic value of the basic clinical information contained in these, and previously published models, is fundamentally of limited value in accurately predicting MPM prognosis. The methods described are suitable for expansion using emerging predictors, including tumour genomics and volumetric staging. Introduction Standard CF genotyping only identifies 94% of CF genes, resulting in the emergence of a "cystic fibrosis screen positive, inconclusive diagnosis" (CFSPID) designation. This, and the advent of genotype-specific CFTR directed therapies has highlighted the need for more comprehensive genotyping, particularly to identify rarer genes when only a single gene is found on initial screening. However, extended CFTR screening is an expensive investigation and we wished to assess its use and yield. Methods Between 2014 and 2016 we identified 40 people with CF attending our large regional adult unit without two known pathogenic CFTR genes and offered them extended CFTR screening. We looked at the yield in terms of additional genes identified and their clinical significance in 37 of these (3 refused/did not attend). Results A new molecular diagnosis (i.e., two pathogenic genes) was made in 18 (48.5%) people with CF. Genes associated with CFTR related disorders were found in a further 2 (5.5%), genes of uncertain pathogenicity were found in 3 (8.1%), and one or no genes were found in 14 (37.8%). Of the 18 people with CF with additional identified genes, 8 had those associated with responsiveness to the CFTR potentiator ivacaftor (4 × 3272-26 AG, 1 × 711+3 AG, 1 × R347H, 1 × 2789+5GA, 1 × S945L) and 2 of these (R347H and S945L) have recently been approved for ivacaftor use by the U.S. Food and Drug Administration. Conclusions In people with a clinical diagnosis of CF but only one pathogenic gene on initial screen, extended CFTR screening identified a second gene in nearly half of cases. Furthermore, a significant proportion of the identified genes have been reported to respond to ivacaftor. It is therefore important that all people with CF without two known mutations undergo extended mutation screening in order to establish who may benefit should the current license for ivacaftor be expanded in the UK.
